Ribavirin And Peginterferon Alfa-2b
Recommended HepatologyAuthority Required
treatment of chronic hepatitis C in children and adolescents with a bodyweight of greater than or equal to 27 kg with compensated liver disease and who have not received previous interferon treatment
2
Submissions
1 resub
2008–11
On the record
$15k
ICER range
1 sourced ICER · 2008
—
Cost basis
Decisions on record
- Meeting Jul 2011 Recommended Hepatitis C infection
- Meeting Jul 2008 Recommended Hepatitis C
- Meeting Jul 2008 Recommended Chronic hepatitis C
Access path
- Jul 2008Recommended · restricted
vs usual standard care
- Jul 2011Recommended · restricted
Comparator changed: usual standard care → standard of care (no treatment)
- PBS listing · Authority Required
RecommendedDeferredNot recommended
Cost-effectiveness
Submission calculated an ICER of less than $15,000 but this was not incorporated as a formal band. PBAC noted uncertainty in the economic model regarding the comparator assumption.
The PBAC considered there was uncertainty in the economic model in the assumption of no treatment as the comparator as this ascribed the cost savings and benefits of current adult treatment to the listing requested. However, overall the PBAC considered that ribavirin with peginterferon alfa-2b for the treatment of chronic hepatitis C in patients under the age of 18 years who have not received previous interferon treatment was of acceptable cost effectiveness. PBAC · 2011
ICER uncertainEconomic model disputedCost-effectiveness accepted
Decision context
Populationpatients under the age of 18 years who have not received previous interferon treatment and weighing at least 27 kg with compensated liver disease
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2011 | Recommended · restricted | standard of care (no treatment) | — | Single-arm · Sustained virological response (SVR) |
| Jul 2008 | Recommended · restricted | usual standard care | $15k | Single-arm · SVR |